Evidence map›Paper›PMID 38679017›Full record

ArticleChemotherapy2024

The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden.

James Alexander Korolewicz, Bernhard Scheiner, Claudia A M Fulgenzi, Antonio D'Alessio, Alessio Cortellini, Chynna Pascual, Aman Mehan, Sarah Partridge, Dorothy M Gujral, Waleed Mohammed and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

James Alexander KorolewiczDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Bernhard ScheinerDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Claudia A M FulgenziDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Antonio D'AlessioDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Alessio CortelliniDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Chynna PascualDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Aman MehanDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Sarah PartridgeDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Dorothy M GujralDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Waleed MohammedDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Oreoluwa MohammedDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Aneta GrzesiakDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Lauren BookerDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Susan CleatorDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Tzveta PokrovskaDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Waqar SaleemDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
James RackieDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Yasmine NeedhamDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Jonathan KrellDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Iain McNeishDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Laura TookmanDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Won-Ho Edward ParkDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Muzamil AsifDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Joanne S EvansDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
David J PinatoDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.

Funding

Wellcome Trust
6 · The paper itself

Abstract

introductionAs tumour response rates are increasingly demonstrated in early-phase cancer trials (EPCT), optimal patient selection and accurate prognostication are paramount. Hammersmith Score (HS), a simple prognostic index derived on routine biochemical measures (albumin <35 g/L, lactate dehydrogenase >450 IU/L, sodium <135 mmol/L), is a validated predictor of response and survival in EPCT participants. HS has not been validated in the cancer immunotherapy era.

methodsWe retrospectively analysed characteristics and outcomes of unselected referrals to our early-phase unit (12/2019-12/2022). Independent predictors for overall survival (OS) were identified from univariable and multivariable models. HS was calculated for 66 eligible trial participants and compared with the Royal Marsden Score (RMS) to predict OS. Multivariable logistic regression and C-index was used to compare predictive ability of prognostic models.

resultsOf 212 referrals, 147 patients were screened and 82 patients treated in EPCT. Prognostic stratification by HS identifies significant difference in median OS, and HS was confirmed as a multivariable predictor for OS (HR: HS 1 vs. 0 2.51, 95% CI: 1.01-6.24, p = 0.049; HS 2/3 vs. 0: 10.32, 95% CI: 2.15-49.62, p = 0.004; C-index 0.771) with superior multivariable predictive ability than RMS (HR: RMS 2 vs. 0/1 5.46, 95% CI: 1.12-26.57, p = 0.036; RMS 3 vs. 0/1 6.83, 95% CI: 1.15-40.53, p < 0.001; C-index 0.743).

conclusionsHS is a validated prognostic index for patients with advanced cancer treated in the context of modern EPCTs, independent of tumour burden. HS is a simple, inexpensive prognostic tool to optimise referral for EPCT.

Indexed as

NeoplasmsPatient SelectionTumor BurdenAdultAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesEarly-phase trial prognostic score

Identifiers

PMID38679017
PMCPMC11614300

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.